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Abstract
Background: Pertussis is a re-emerging disease worldwide despite its high vaccination coverage. European and
Latin-American countries have used different surveillance and vaccination policies against pertussis. We compared
the epidemiology of this disease in two Ibero-American countries with different vaccination and surveillance
policies.
Methods: We compared the epidemiology of pertussis in Spain and the Dominican Republic (DR). We present a
10-year observational study of reported pertussis based on suspected and/or probable cases of pertussis identified
by the national mandatory reporting system in both countries between 2005 and 2014. Both countries have a
similar case definition for pertussis surveillance, although Spain applies laboratory testing, and uses real time PCR
and/or culture for case confirmation while in DR only probable and/or suspected cases are reported. We analyzed
incidence, hospitalization, case-fatality rates, mortality and vaccination coverage.
Results: The average annual incidence in children aged <1 year was 3.40/100,000 population in Spain and 12.15/
100,000 in DR (p = 0.01). While the incidence in DR was generally higher than in Spain, in 2011 it was six times
higher in Spain than in DR. The highest infant mortality in Spain was 0.017/100,000 in 2011, and the highest in DR
was 0.08/100,000 in 2014 (p = 0.01). The proportion of hospitalized cases per year among children <1 year varied
between 22.0% and 93.7% in Spain, and between 1.1% and 29.4% in DR (p = 0.0002), while mortality varied from 0
to 0.017 and 0 to 0.08 per 100,000 population in Spain and DR, respectively (p = 0.001). Vaccination coverage was
96.5% in Spain and 82.2% in DR (p = 0.001).
Conclusions: Pertussis is a public health problem in both countries. Surveillance, prevention and control measures
should be improved, especially in DR. Current vaccination programs are not sufficient for preventing continued
pertussis transmission, even in Spain which has high vaccination coverage.
Keywords: Bordetella pertussis, Whooping cough, Infectious disease epidemiology, Surveillance, Spain, Dominican
Republic
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Background
Approaches to surveillance, prevention (including
immunization) and control of pertussis vary markedly
worldwide, even between European countries. For
good epidemiological control of mandatory notifiable
diseases such as pertussis, it is important to limit
under-reporting, and to have alternative surveillance
systems in place (microbiology results, hospital
discharges, etc.). The current incidence of this disease
seems to be influenced by vaccination coverage, since
most countries with extensive pertussis vaccine cover-
age in infants have achieved a significant reduction in
morbidity and mortality in this population [1, 2].
However, several studies have reported differences in
pertussis incidence in countries with different vaccination
programs [1, 3, 4]. Laboratory surveillance is essential for
guiding vaccination policy, but this surveillance is lacking
in many Latin-American countries. The general lack of
specific laboratory diagnosis by real time polymerase chain
reaction (PCR) and serology in Latin America is a major
technology gap in the region’s ability to effectively control
pertussis [5].
Reports from several regions in Spain and in some
Latin-American countries highlight increased incidence,
hospitalization and mortality due to pertussis infection,
especially among infants who are too young to be immu-
nized [6–9].
European and Latin-American countries have used
different vaccination strategies against pertussis (Table 1)
[10]. In most European Union countries, whole-cell per-
tussis vaccines have recently been replaced with acellular
vaccine combinations containing diphtheria, tetanus
toxoids and pertussis components (DTaP and Tdap).
However, pertussis remains endemic despite high cover-
age with whole-cell (DTwP) or acellular (DTaP) vaccines.
This is likely due to decreasing immunity, and demands
new vaccination strategies that provide long-lasting im-
munity [11]. Hegerle N et al. reported in 2014 that some
new strains of pertussis show a loss in production of
pertactin (prn), a virulence factor included in various
acellular pertussis vaccines against both B. pertussis and
the closely related B. parapertussis. This phenomenon
highlights the need to reassess the efficacy and effective-
ness of these vaccines [12].
The aim of this study was to compare the epidemiology
of pertussis in two geographically distant countries, Spain
and the Dominican Republic (DR), which have different
vaccination and surveillance policies.
Methods
Data sources
Reports of clinically suspected and laboratory confirmed
cases of pertussis in Spain and DR during 2005-2014
were obtained from the Spanish Epidemiological Surveil-
lance Network at the National Centre for Epidemiology,
Carlos III Health Institute (RENAVE-CNE-ISCIII), and
the Dominican Ministry of Health and Social Assistance
Expanded Program on Immunization (SESPAS-PAI),
respectively. Additional information regarding vaccination
status was recovered from epidemiological records, where
available. Data on pertussis-related hospital admissions
and deaths were obtained from the Spanish national mini-
mum basic data set (MBDS) and from the Institutes of
Statistics in both countries, respectively [13–15].
Hospitalization data were obtained from the Ministry
of Health, Social Services and Equality in Spain, and
from the Ministry of Health in DR. We used demo-
graphic data from the National Statistics Office of each
country to calculate rates of incidence, hospitalization
and mortality between 2005 and 2014, and for each sex
and age group [16]. Because of a lack of laboratory con-
firmation, it was not possible to assess progression of
confirmed cases in DR.
Definitions
In Spain, the clinical case definition for pertussis was
that established by RENAVE-CNE-ISCIII: until 2012 it
was “a cough lasting ≥2 weeks, followed by paroxysmal
cough, inspiratory whoop, post-tussive vomiting in
absence of other apparent cause”. Since 2013 apnea in
infants younger than 1 year of year was added as clinical
criteria. Laboratory case confirmation was performed on
nasopharyngeal secretion samples using culture (Bordet-
Gengou and/or Regan-Lowe) and/or PCR for nucleic
Table 1 Incidence of notified pertussis, vaccines, vaccination schedules and coverage in Spain and Dominican Republic, 2005–2014
Country Global Incidence
per 100,000 inhab.a
Incidence per 100,000
inhab. ≤1 year-old
Vaccine Manufacturer Global
coverageb (%)
Vaccination Schedulec
(type vaccine)
Spain
(Iberian country)
3.4 (0.5–8,4) 813.3 Infanrix Hexa®
Infanrix
VPI Hib®
Pentavac®
GlaxoSmithKline Biologicals,
S.A.
Sanofi Pasteur MSD, S.A.
96.5 Primary: 2, 4, 6 mo.
Booster: 15–18 mo
and 4–6 yr (DTaP)
DR
(Caribbean country)
12.1 (1.0–37.0) 132.0 Quinvaxem®
Tritanrix® HB
DTCHepB.Hib®
GlaxoSmithKline Biologicals,
S.A.
82.2 Primary: 2, 4, 6 mo.
Booster: 18 mo and
4 yr (DTwP)
aCare should be taken when comparing incidences between countries because of the different surveillance and diagnostic methods used
bcoverage in children aged 2, 4 and 6 months (primary series coverage in children)
ctwo booster doses are given in DR and Spain at the age of 18 months and 4 years-old, and between 4–6 years
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acid detection of B. pertussis in clinical samples. Suspected
cases were required to meet the clinical case definition
established by RENAVE-CNE-ISCIII. Until 2011, probable
cases were those that met the clinical case definition, were
not laboratory confirmed and were not epidemiologically
linked to a laboratory confirmed case. In 2013, probable
cases were considered those that met the clinical case
definition and were epidemiologically linked with a labora-
tory confirmed case [17, 18].
In DR, positive cases of pertussis were diagnosed
according to the World Health Organization’s clinical case
definition: “a cough lasting ≥2 weeks with at least one of
the following symptoms: paroxysms of coughing, inspira-
tory whooping or post-tussive vomiting or apnea without
other apparent causes”, and cases were not laboratory-
confirmed [19].
The cause of hospitalization was considered to be pertus-
sis in cases where the main diagnosis was coded as 033.0/
033.1/033.8/033.9 according to the International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) [20].
Immunization scheme and coverage
Vaccinations included in the childhood immunization
schedule in Spain are financed by the National Health
System (SNS), and are performed according to the
recommendations of the Spanish Inter-territorial
Council. These recommendations take into account
epidemiological data, as well as evidence regarding
the safety, effectiveness and efficiency of current
vaccines. During the study period, Spanish children
received either DTaP (Infanrix hexa®) at the age of 2,
4, and 6 months. The Spanish SNS switched to using
acellular vaccines in 2005, and the currently recom-
mended DTaP vaccination schedule at a national level
consists of DTaP at the age of 2, 4, 6, and 18 months,
followed by a reminder dose between the age of 4
and 6 years [21].
The immunization schedule for Dominican children
aged 2 months to 6 years includes (Quinvaxem®) and
(Tritanrix-HB +HIBERIX®) vaccines, both including
DTwP. In DR the DTwP vaccine is recommended at 2,
4, 6 and 18 months, and 4 years of age, and is financed
by the Pan American Health Organization (PAHO) [20].
Cases who had received all vaccination doses corre-
sponding to their age were classified as adequately
vaccinated. Cases who had received fewer than the ap-
propriate number of doses for their age were classified
as inadequately vaccinated. Cases who had received no
vaccination at all were classified as unvaccinated. Vac-
cination status in both countries was ascertained from
the patient’s vaccination card, or from the correspond-
ing surveillance system (updated by the visiting phys-
ician based on an oral report by the child’s mother).
Statistical analysis
We performed a descriptive analysis of the patients’ clinical
characteristics, and of the presenting illness and its progres-
sion over time. For this analysis, we searched for association
between key characteristics of pertussis and mortality.
The following age groups were considered for the
analysis: <1, 1-4, 5-9, 10-14 and ≥15 years of age.
Statistical significance of observed associations was
evaluated using the Chi-square or Fisher’s exact test for
categorical variables, and the Wilcoxon rank-sum test
for continuous variables. Statistical significance was set
at p < 0.05 for all analyses. All statistical analyses were
performed using the Statistical Package for Social
Sciences (SPSS® version 18.0, Chicago, IL, USA) for
Windows (Microsoft Corp., Redmond, WA, USA).
Results
Number of cases, incidence, hospitalizations and deaths
In Spain, there were 4,578, 3,147, 2,392 and 2,153 reported
cases of pertussis among children aged <1, 1-4, 5-9, and
10–14 years, respectively, and 3,470 among adolescents
and adults aged ≥15 years. The number of laboratory-
confirmed cases in these age groups was 54.6% (2502/
4,578), 37.0% (1163/3147), 46.9% (1122/2392), 47.4%
(1020/2153) and 40.2% (1394/3470), respectively, and the
number of probable cases was 45.3% (2076/4,578), 63.1%
(1984/3147), 53.1% (1270/2392), 52.6% (1133/2153),
respectively.
In DR, 260 cases were reported among infants <1 year,
and only 4 cases were reported in children aged 1-4
years. No cases were reported in the other age groups.
All cases were categorized as suspected or probable
cases (median 1.0).
The overall incidence of pertussis in DR was higher
than in Spain, especially in 2014, although there was an
isolated inversion of this trend in 2011, when the inci-
dence in Spain was six times that in DR (Fig. 1). The
specific peak of incidence in DR underwent an upward
trend in between 2012 to 2014.
The highest differences between the two countries in
terms of the epidemiological indicators studies were in
the 2014 incidence (37.0/100,000 in DR and 7.18/
100,000 in Spain), the 2014 hospitalization rate (0.78/
100,000 inhabitants in DR and 1.7/100,000 in Spain),
and the 2014 mortality (0.08/100,000 in DR and 0.001/
100,000 inhabitants in Spain).
As of 2010, the number of hospitalizations due to
pertussis increased in Spain, peaking in 2011 with 2.3
hospitalizations per 100,000 inhabitants. The trend in
age-standardized hospitalizations was similar to that
for case reports in both countries (Fig. 1); however,
the rates varied throughout the study period. In Spain,
the percentage of hospitalized cases was very high
during the initial years of the study (2005–2006;
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88.6%–93.7%), but was only 20–40% between 2011
and 2014. In DR, 23.3% and 29.4% of cases were
hospitalized in 2005 and 2014, respectively.
The rate of mortality due to pertussis in Spain was
0.01, 0.02 and 0.01 per 100,000 inhabitants in 2008,
2011 and 2012, respectively. All deaths due to pertus-
sis in both countries occurred in young infants who
were incompletely immunized or unvaccinated. In
DR, data on the number of deaths caused by pertussis
were only available for 2005 and 2012–2014, and were
limited to the <1 year age group (Fig. 1). Pertussis
mortality increased significantly from 0.04 to 0.08 per
100,000 inhabitants between 2005 and 2014 (p = 0.01).
Also, the case-fatality rate was higher in DR, reaching
25.4% and 50.0% in 2005 and 2014, respectively; con-
versely, in Spain, it tended to stay below 5% (Fig. 2).
Vaccination status
Throughout the study period, the overall rate of vaccination
coverage was 96.5% in Spain and 82.2% in DR (p = 0.001)
(Table 1). Coverage in DR varied significantly between
regions, ranging from 66.1% to 88.0%.
The profiles of vaccinated children and those with
unknown vaccination status differed between countries;
54.2% of cases aged <1 year in Spain had an adequate
vaccination status, while in DR this rate was 10.3%. The
percentage of unvaccinated children <1 year of age was
higher in DR (51.0%) than in Spain (4.4%) (p = 0.001);
among 1- to 4-year-olds this value was 45.5% and 0%,
respectively. The proportion of children with pertussis diag-
nosis and vaccination status in both countries, are show in
Fig. 3a and b. Furthermore, among notified cases with
information on immunization status, 19.4% of children
Fig. 1 Age-standarized incidence, and rates of hospitalization and mortality due to pertussis in Spain and the Dominican Republic, 2005–2014
Fig. 2 Evolution of case-fatality rates of pertussis in Spain and the Dominican Republic, 2005–2014
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aged 5–9 had receive four doses of vaccine in Spain. There-
fore, the highest proportion of adequately vaccinated pa-
tients was in children <1 year with a high incidence rate of
813.3/100,000 inhabitants. The ≥15 years age group had the
highest percentage of cases with unknown immunization
status (94.4%). In DR, most of the information collected
regarding the vaccination status of children refers to the
first series of DTwP vaccinations, because most reported
cases (95.1%) were children aged <1 year.
In Spain, 31.4% of children aged 1–4 had unknown
immunization status. In the <1 year age group, the
proportion of cases with unknown immunization sta-
tus was low in both Spain and DR (19.0% and 31.4%,
respectively).
Discussion
In this study carried out in Spain and DR, we observed
important differences in pertussis epidemiology: higher
incidence, and case-fatality and mortality rates in DR,
but higher rates of hospitalization and vaccination cover-
age in Spain.
These data show that pertussis is still a public health
problem both in Spain and DR. Also, surveillance data
in DR support the need for improvement because of the
potential importance of under-reporting (low incidence
and vaccination coverage, combined with a high case
fatality rate) [22]. Furthermore, none of the cases in DR
were laboratory-confirmed, but rather were diagnosed as
pertussis by physicians on the basis of clinical symptoms.
Fig. 3 a Reported cases of pertussis according to vaccination status, and incidence rate, stratified by age group. Spain, 2005–2014. b Reported
cases of pertussis according to vaccination status, and incidence rates, stratified by age groups. Dominican Republic, 2005–2014
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These deficiencies in the surveillance of pertussis have
also been reported in other Latin-American countries
[22, 23].
Overall, most cases in these countries are diagnosed on
the basis of bacterial culture, the sensitivity of which varies
according to the stage of the infection [24, 25]. Adherence
to screening recommendations and access to healthcare
influence early detection of pertussis infection. However,
in Spain these recommendations are not followed consist-
ently. In this sense, routine pertussis screening has been
performed since the 1990s during outbreaks in the USA
in settings such as schools, day care centers, and hospitals
(for symptomatic patients with suspected pertussis), which
promotes prompt administration of antibiotics for high
risk close contacts and suspected cases [26, 27].
Incidence
Several aspects could have influenced the results of this
study. For example, it is important to highlight under-
reporting as a persistent problem in controlling infectious
diseases, despite mandatory notification by physicians. We
must also consider possible differences in the quality of
historical data and overall management of surveillance,
prevention and control of contacts, as noted in other
studies [28–30].
Interestingly, epidemiological data show that pertussis
incidence has increased in all age groups in Latin-
America and Europe, where acellular pertussis vaccines
are used, although an increase was also observed in
some countries that use whole-cell vaccines, such as DR,
where vaccine coverage is low, and implementing and
improving laboratory diagnostic methods is crucial [31].
For this reason, some European countries have shifted
from pertussis testing based on risk assessment to
pertussis screening in certain households, schools and
community settings. This screening consists of testing
for infections in asymptomatic people, a protocol that is
never used in DR and rarely in Spain [32–35].
Hospitalization
Similarly, the percentage of hospitalized cases is condi-
tioned by the quality of the monitoring and case reporting.
The high rate of pertussis hospitalization in young infants
in both countries considered in this study may be due to a
tendency to only report serious cases to their respective
surveillance systems.
Another factor that may have influenced our results is
the lack of access to health-care insurance in DR, with a
mortality rate of 0.3 deaths per 1,000 live births in 2008.
The main causes were child malnutrition and commu-
nicable diseases (acute respiratory diseases), which are
notably more common than in other Latin American
and Caribbean countries with similar economic condi-
tions [36].
The percentage of cases with confirmed diagnosis was
highest in Spain, which has increasing hospitalization
rates, and the majority (92%) of hospitalizations oc-
curred in children under one year of age. However,
between 2011 and 2014, hospitalization trends in Spain
have begun to approach reality because of improved
reporting and hospitalization of cases of pertussis [20].
There was also a significant increase in hospitalization
rates during the study period in both countries due to
more accurate and timely reporting of hospitalizations,
which represent the most severe cases, as a result of
using electronic disease-reporting systems [37, 38]. In the
USA, a similar time trend was reported in children
hospitalized with bronchiolitis during the months of
November to March, between 2007 to 2010 [39].
Mortality
The average infant mortality in Spain was ~3.1 deaths
per 1,000 live births in 2012, which is below average for
the European Union (4/1000 live births) [15]. The
infant mortality rate in DR was ~21.3 per 1,000 live
births in 2012, decreasing to ~19.6 per 1,000 live births
in 2014. Previous studies have analyzed the main causes
of death in children in Spain, namely cancer, heart and
cerebrovascular diseases, and some infectious diseases,
including pertussis [40, 41]. This confirms the need to
modify vaccination strategies in this country to better
serve the most vulnerable population groups [8]. The
first should involve vaccinating pregnant women, which
directly protects through the passive transfer of pertussis
antibodies. The second strategy, cocooning, involves
vaccinating parents, caregivers, and other close contacts,
which indirectly protects infants from transmission by
preventing disease in those in close proximity [42].
The overall mortality rate in DR rose from 5.99% in
2003 to 6.03% in 2012 and 6.05% in 2013, exacerbating
the country’s mortality rate ranking in Latin-America.
Insufficient coverage by the health system, underreporting
of disease, lack of medical certification, and ill-defined
certificates are some of the barriers to understanding and
evaluating the current processes [14, 43].
Vaccination
In 2007, pentavalent (DPT-HB-Hib) vaccination cover-
age (69.6%) among children aged <1 year was low in DR,
a country where less than half the population has health
insurance [14]. This may also be due to high rates of
social disadvantage together with a lack of a network of
social and family support. However, Latin-American
countries have good capacity to conduct vaccination
programs, and there is generous government support, in
accordance with World Health Organization (WHO)
recommendations issued since 1992 [44]. The Revolving
Fund of the Pan American Health Organization (PAHO)
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contributed to this achievement by pushing forward
policy changes that support national immunization pro-
grams, such as vaccine legislation and economic actions
to ensure the delivery of services [45]. Whole-cell
pertussis vaccines (DTwP), which appear to be quite
effective, are used throughout Latin America. A 4-dose
schedule is typically used (2, 4, 6 and 18 months), and a
booster dose is given between the ages of 4 and 6; this
treatment reaches >90% of the population in most regions,
but is incomplete in regions with political or geographical
barriers, resulting in poor uptake of combination vaccines
and low coverage [9, 46]. The situation in Spain is
different to that in DR, suggesting a progressive
accumulation of susceptible individuals due to waning
immunity following years of low incidence [6, 47–49].
In 2015, Spain adopted the recommendation to vaccinate
pregnant women as an alternative immunization strategy to
protect newborns, with the aim of protecting infants during
the first weeks of life [19, 50].
The Advisory Committee on Vaccines of the Spanish
Association of Paediatrics updated their immunization
schedule and only reasserts its recommendation to
include vaccination strategies, with dTap for pregnant
women and household contacts of the newborn [51].
Currently, no data are available in both countries to
know about levels of compliance with the gynaecologists'
and public health services' recommendation to vaccinate
pregnant women.
In Spain there is now an ongoing project to estimate
the effectiveness of the vaccine in pregnant women.
A possible limitation of this work is the fact that it is a
retrospective database study, which makes it difficult to
capture all of the relevant information for the 10-year
period studied. The use of SESPAS-PAI surveillance data
for case detection in DR could result in under-estimation
of infection rates. A further limitation was that suspected
and probable reported cases in DR, these cases were
subjectively assessed according to clinical criteria were not
specifically of pertussis, such as lymphocytosis. Lack of
comprehensive data from the surveillance system in DR
results in several limitations, and the underestimation of
pertussis in all age groups may be mainly related to its
atypical clinical manifestations and the lack of laboratory
confirmation (clinical and demographic survey data).
Implications for public health policy
It is difficult to compare the epidemiology of pertussis in
Spain and DR. The mandatory notification system in DR
is not very effective, and laboratory confirmation is not
done, making it impossible to determine the true epidemio-
logical incidence in this country. The differences in
historical health policies seem more determinative in
this comparison, and there is a need to improve the
vaccination coverage with effective vaccines. The
difference in age patterns of reported cases between
countries likely accounts for this contrasting observa-
tion. Despite the lack of comprehensive data in DR,
this should not hamper the use of active prophylactic
measures designed to limit the impact of waning
immunity against pertussis. Most children were likely
to have received three doses of DTaP vaccine in Spain
and DTwP vaccine in DR within the first year of life.
The profiles of vaccinated children and those with
unknown vaccination status were different in each
country.
Conclusions
The observed differences between the two countries sug-
gest that pertussis control programs should be improved by
developing new active surveillance systems, vaccination
strategies and diagnostic technologies, especially in DR. We
provide lessons for the future evaluation of public health
interventions. The results of several studies in Belgium and
the UK support the recommendation to immunize during
pregnancy, and provide additional evidence of possible
interference by maternal antibodies to the fetus. This
reduces incidence and mortality in children <1 year-old
[52, 53], so it would be advisable to adopt this policy
systematically in both Spain and DR.
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